Published in Diabetes Obes Metab on July 08, 2015
GLP-1 and weight loss: unraveling the diverse neural circuitry. Am J Physiol Regul Integr Comp Physiol (2016) 0.78
Current status of intragastric balloon for obesity treatment. World J Gastroenterol (2016) 0.76
Update on bariatric surgical procedures and an introduction to the implantable weight loss device: the Maestro Rechargeable System. Med Devices (Auckl) (2016) 0.75
What weight loss treatment options do geriatric patients with overweight and obesity want to consider? Obes Sci Pract (2016) 0.75
The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients. Front Psychiatry (2017) 0.75
Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health. Obes Res (1998) 50.73
The disease burden associated with overweight and obesity. JAMA (1999) 19.39
Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA (2013) 18.86
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet (2009) 15.00
Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann Intern Med (2013) 9.66
The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet (2008) 9.03
Systematic review: an evaluation of major commercial weight loss programs in the United States. Ann Intern Med (2005) 8.00
Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ (2012) 5.57
XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care (2004) 5.34
Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA (2012) 5.15
Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med (2005) 4.04
Review of the key results from the Swedish Obese Subjects (SOS) trial - a prospective controlled intervention study of bariatric surgery. J Intern Med (2013) 3.49
American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. Endocr Pract (2012) 3.29
Depression and obesity: a meta-analysis of community-based studies. Psychiatry Res (2010) 2.64
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) (2010) 2.25
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) (2011) 2.09
A proposed clinical staging system for obesity. Int J Obes (Lond) (2009) 2.09
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 2.08
Pharmacological management of obesity: an endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2015) 2.05
Improved lifestyle and decreased diabetes risk over 13 years: long-term follow-up of the randomised Finnish Diabetes Prevention Study (DPS). Diabetologia (2012) 1.99
A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab (2011) 1.98
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr (2011) 1.94
Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring) (2012) 1.66
Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2005) 1.64
Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J (2013) 1.62
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) (2013) 1.60
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab (2009) 1.52
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care (2010) 1.50
A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res (2003) 1.48
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) (2013) 1.46
Aace/Ace comprehensive diabetes management algorithm 2015. Endocr Pract (2015) 1.43
Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond) (2013) 1.39
Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme. Diabetes Obes Metab (2012) 1.34
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care (2013) 1.32
Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov (2006) 1.30
Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Diabetes Obes Metab (2013) 1.29
Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997. MMWR Morb Mortal Wkly Rep (1997) 1.27
The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med (2013) 1.22
The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring) (2013) 1.21
Comorbidities of obesity. Prim Care (2009) 1.20
Metformin and body weight. Int J Obes (Lond) (2007) 1.18
High prevalence of obesity, central obesity and abnormal glucose tolerance in the middle-aged Finnish population. BMC Public Health (2008) 1.15
Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring) (2014) 1.07
The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy (2013) 1.06
Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release. Diabetes Care (2013) 1.03
Blood pressure and heart rate effects, weight loss and maintenance during long-term phentermine pharmacotherapy for obesity. Obesity (Silver Spring) (2011) 1.02
Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial. Diabetes Obes Metab (2015) 0.90
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obesity (Silver Spring) (2013) 0.86
Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications (2014) 0.86
Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring) (2013) 0.83
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab (2013) 0.82
Obesity and polycystic ovary syndrome. Minerva Endocrinol (2014) 0.80
Pragmatic study of orlistat 60 mg on abdominal obesity. Eur J Clin Nutr (2011) 0.79
Lixisenatide as add-on to oral anti-diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes. Diabetes Metab Res Rev (2014) 0.79
Obesity as a disease: the Obesity Society Council resolution. Obesity (Silver Spring) (2008) 0.78
Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. J Hypertens (2014) 0.77
Bariatric surgery as a highly effective intervention for diabetes: news flash or preaching to the choir?: comments on "obesity, type 2 diabetes mellitus, and other comorbidities". Arch Surg (2012) 0.77